After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient well-being, particularly for those with rare diseases.
- Home |
- ‘It’s really a dire time for patients’: Biohaven CEO says FDA red tape is blocking access to rare disease treatments
‘It’s really a dire time for patients’: Biohaven CEO says FDA red tape is blocking access to rare disease treatments
- February 13, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
